The <i>HRD</i> Decision<i>-</i>Which PARP Inhibitor to Use for Whom and When.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28974545.
- Also identified by DOI 10.1158/1078-0432.CCR-17-2186 and PMC identifier 5712252.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Rucaparib, a polyADPribose polymerase inhibitor (PARPi), was approved recently for use in women with high-grade serous ovarian cancer (HGSOC). It is now one of three approved PARPi for use in recurrent ovarian cancer, a family of agents that has changed the HGSOC treatment landscape and outcome. <i>Clin Cancer Res; 23(23); 7155-7. ©2017 AACR</i><i>See related article by Balasubramaniam et al., p. 7165</i>.
Medical subject headings
- Ovarian Neoplasms
- Poly(ADP-ribose) Polymerase Inhibitors